The use of a biological preparation in the treatment of some gynaecological diseases.
A double-blind between-patient trial was carried out in 200 women suffering from dysfunctional menorrhagia (142) or from menorrhagia associated with uterine fibromyomatosis (58) to assess and compare the effectiveness of a polypeptide preparation ('Lysometra') and methylandrostendiol in reducing hyperoestrogenism and clinical symptoms. Three 20-day courses of intramuscular injections of either 2.5 ml 'Lysometra' or 5 mg methylandrostendiol were given to matched pairs of patients, with an 8-day interval between. Results, as assessed by absolute and percentage changes in total urine oestrogen levels and by overall clinical response of patients, showed that 'Lysometra' produced a statistically significant greater effect than methylandrostendiol. The biological preparation was well tolerated and no unwanted side-effects were reported.
D000734:Androstenediols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004967:Estrogens / Q000652:urine; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007889:Leiomyoma / Q000150:complications; D008595:Menorrhagia / Q000188:drug therapy*; D008695:Methandriol / Q000008:administration & dosage / Q000627:therapeutic use*; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000150:complications
D000734:Androstenediols; D004967:Estrogens; D010455:Peptides; C012411:lysometra; D008695:Methandriol